MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors

Neoplasia

Volumn 9, Issue 8, 2007, Pages 671-677

  Holtkamp, Nikola ^a   Atallah, Isis ^a   Okuducu, Ali Fuat ^b   Mucha, Jana ^c   Hartmann, Christian ^c   Mautner, Victor F ^d   Friedrich, Reinhard E ^d   Mawrin, Christian ^e   Von Deimling, Andreas ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Helios Klinkum Emil von Behring   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Malignant peripheral nerve sheath tumor; Malignant progression; Matrix metalloproteinase 13; Neurofibromatosis type 1; TP53

Indexed keywords

COLLAGENASE 3; PROTEIN P53;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; METASTASIS; NERVE SHEATH TUMOR; NEUROFIBROMA; NEUROFIBROMATOSIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM;

EID: 34548215196     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07304     Document Type: Article

References (42)

1. Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, and Ilstrup DM (1986). Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 57, 2006-2021.
2. Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, and Moran A (2002). Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 39, 311-314.
3. Huson SM (1994). Neurofibromatosis 1: a clinical and genetic overview. In The Neurofibromatoses. SM Huson and RAC Hughes (Eds). Chapman and Hall Medical, London. pp. 160-203.
4. Birindelli S, Perrone F, Oggionni M, Lavarino C, Pasini B, Vergani B, Ranzani GN, Pierotti MA, and Pilotti S (2001). Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors. Lab Invest 81, 833-844.
5. Mawrin C, Kirches E, Boltze C, Dietzmann K, Roessner A, and Schneider-Stock R (2002). Immunohistochemical and molecular analysis of p53, RB, PTEN in malignant peripheral nerve sheath tumors. Virchows Arch 440, 610-615.
6. Menon AG, Anderson KM, Riccardi VM, Chung RY, Whaley JM, Yandell DW, Farmer GE, Freiman RN, Lee JK, Li FP, et al. (1990). Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in Recklinghausen neurofibromatosis. Proc Natl Acad Sci USA 87, 5435-5439.
7. Holtkamp N, Mautner V, Friedrich R, Harder A, Hartmann C, Theallier-Janko A, Hoffmann K, and von Deimling A (2004). Differentially expressed genes in neurofibromatosis 1-associated neurofibromas and malignant peripheral nerve sheath tumors. Acta Neuropathol Berl 107, 159-168.
8. Levy P, Bieche I, Leroy K, Parfait B, Wechsler J, Laurendeau I, Wolkenstein P, Vidaud M, and Vidaud D (2004). Molecular profiles of neurofibromatosis type 1-associated plexiform neurofibromas: identification of a gene expression signature of poor prognosis. Clin Cancer Res 10, 3763-3771.
9. Ashworth JL, Murphy G, Rock MJ, Sherratt MJ, Shapiro SD, Shuttleworth CA, and Kielty CM (1999). Fibrillin degradation by matrix metalloproteinases: implications for connective tissue remodelling. Biochem J 340, 171-181.
10. Knauper V, Cowell S, Smith B, Lopez-Otin C, O'Shea M, Morris H, Zardi L, and Murphy G (1997). The role of the C-terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction. J Biol Chem 272, 7608-7616.
11. Knauper V, Lopez-Otin C, Smith B, Knight G, and Murphy G (1996). Biochemical characterization of human collagenase-3. J Biol Chem 271, 1544-1550.
12. Mitchell PG, Magna HA, Reeves LM, Lopresti-Morrow LL, Yocum SA, Rosner PJ, Geoghegan KF, and Hambor JE (1996). Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J Clin Invest 97, 761-768.
13. Johansson N, Vaalamo M, Grenman S, Hietanen S, Klemi P, Saarialho-Kere U, and Kahari VM (1999). Collagenase-3 (MMP-13) is expressed by tumor cells in invasive vulvar squamous cell carcinomas. Am J Pathol 154, 469-480.
14. Airola K, Karonen T, Vaalamo M, Lehti K, Lohi J, Kariniemi AL, Keski-Oja J, and Saarialho-Kere UK (1999). Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas. Br J Cancer 80, 733-743.
15. Etoh T, Inoue H, Yoshikawa Y, Barnard GF, Kitano S, and Mori M (2000). Increased expression of collagenase-3 (MMP-13) and MT1-MMP in oesophageal cancer is related to cancer aggressiveness. Gut 47, 50-56.
16. Pendas AM, Uria JA, Jimenez MG, Balbin M, Freije JP, and Lopez-Otin C (2000). An overview of collagenase-3 expression in malignant tumors and analysis of its potential value as a target in antitumor therapies. Clin Chim Acta 291, 137-155.
17. Ala-Aho R, Johansson N, Baker AH, and Kahari VM (2002). Expression of collagenase-3 (MMP-13) enhances invasion of human fibrosarcoma HT-1080 cells. Int J Cancer 97, 283-289.
18. Ala-aho R, Ahonen M, George SJ, Heikkila J, Grenman R, Kallajoki M, and Kahari VM (2004). Targeted inhibition of human collagenase-3 (MMP-13) expression inhibits squamous cell carcinoma growth in vivo. Oncogene 23, 5111-5123.
19. Ala-aho R, Grenman R, Seth P, and Kahari VM (2002). Adenoviral delivery of p53 gene suppresses expression of collagenase-3 (MMP-13) in squamous carcinoma cells. Oncogene 21, 1187-1195.
20. Sun Y, Cheung JM, Martel-Pelletier J, Pelletier JP, Wenger L, Altman RD, Howell DS, and Cheung HS (2000). Wild type and mutant p53 differentially regulate the gene expression of human collagenase-3 (hMMP-13). J Biol Chem 275, 11327-11332.
21. Coindre JM, Trojani M, Contesso G, David M, Rouesse J, Bui NB, Bodaert A, De Mascarel I, De Mascarel A, and Goussot JF (1986). Reproducibility of a histopathologic grading system for adult soft tissue sarcoma. Cancer 58, 306-309.
22. Guillou L, Coindre JM, Bonichon F, Nguyen BB, Terrier P, Collin F, Vilain MO, Mandard AM, Le Doussal V, Leroux A, et al. (1997). Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 15, 350-362.
23. Airola K, Johansson N, Kariniemi AL, Kahari VM, and Saarialho-Kere UK (1997). Human collagenase-3 is expressed in malignant squamous epithelium of the skin. J Invest Dermatol 109, 225-231.
24. Lothe RA, Smith-Sorensen B, Hektoen M, Stenwig AE, Mandahl N, Saeter G, and Mertens F (2001). Biallelic inactivation of TP53 rarely contributes to the development of malignant peripheral nerve sheath tumors. Genes Chromosomes Cancer 30, 202-206.
25. Balbin M, Pendas AM, Uria JA, Jimenez MG, Freije JP, and Lopez-Otin C (1999). Expression and regulation of collagenase-3 (MMP-13) in human malignant tumors. APMIS 107, 45-53.
26. Uria JA, Stahle-Backdahl M, Seiki M, Fueyo A, and Lopez-Otin C (1997). Regulation of collagenase-3 expression in human breast carcinomas is mediated by stromal-epithelial cell interactions. Cancer Res 57, 4882-4888.
27. Kurtz A and Martuza RL (2002). Antiangiogenesis in neurofibromatosis 1. J Child Neurol 17, 578 -584 (discussion, 602-574, 646-551).
28. Mousses S, McAuley L, Bell RS, Kandel R, and Andrulis IL (1996). Molecular and immunohistochemical identification of p53 alterations in bone and soft tissue sarcomas. Mod Pathol 9, 1-6.
29. Yoo J, Lee HK, Kang CS, Park WS, Lee JY, and Shim SI (1997). p53 gene mutations and p53 protein expression in human soft tissue sarcomas. Arch Pathol Lab Med 121, 395-399.
30. Cichowski K, Shih TS, Schmitt E, Santiago S, Reilly K, McLaughlin ME, Bronson RT, and Jacks T (1999). Mouse models of tumor development in neurofibromatosis type 1. Science 286, 2172-2176.
31. Vogel KS, Klesse LJ, Velasco-Miguel S, Meyers K, Rushing EJ, and Parada LF (1999). Mouse tumor model for neurofibromatosis type 1. Science 286, 2176-2179.
32. Kim EL, Yoshizato K, Kluwe L, Meissner H, Warnecke G, Zapf S, Westphal M, Deppert W, and Giese A (2005). Comparative assessment of the functional p53 status in glioma cells. Anticancer Res 25, 213-224.
33. An WG, Kanekal M, Simon MC, Maltepe E, Blagosklonny MV, and Neckers LM (1998). Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature 392, 405-408.
34. Koong AC, Denko NC, Hudson KM, Schindler C, Swiersz L, Koch C, Evans S, Ibrahim H, Le QT, Terris DJ, et al. (2000). Candidate genes for the hypoxic tumor phenotype. Cancer Res 60, 883-887.
35. Watanabe T, Oda Y, Tamiya S, Masuda K, and Tsuneyoshi M (2001). Malignant peripheral nerve sheath tumour arising within neurofibroma. An immunohistochemical analysis in the comparison between benign and malignant components. J Clin Pathol 54, 631-636.
36. Johansson N, Ala-aho R, Uitto V, Grenman R, Fusenig NE, Lopez-Otin C, and Kahari VM (2000). Expression of collagenase-3 (MMP-13) and collagenase-1 (MMP-1) by transformed keratinocytes is dependent on the activity of p38 mitogen-activated protein kinase. J Cell Sci 113 (Part 2), 227-235.
37. Wang-Gohrke S, Becher H, Kreienberg R, Runnebaum IB, and Chang-Claude J (2002). Intron 3 16 bp duplication polymorphism of p53 is associated with an increased risk for breast cancer by the age of 50 years. Pharmacogenetics 12, 269-272.
38. Verselis SJ and Li FP (2000). Common polymorphism in p53 intron 2, IVS2 + 38G→C. Hum Mutat 16, 181.
39. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, and Matlashewski G (1999). Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19, 1092-1100.
40. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G, and Banks L (1998). Role of a p53 polymorphism in the development of human papillomavirus - associated cancer. Nature 393, 229-234.
41. Dumont P, Leu JI, Della Pietra AC III, George DL, and Murphy M (2003). The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33, 357-365.
42. Pietsch EC, Humbey O, and Murphy ME (2006). Polymorphisms in the p53 pathway. Oncogene 25, 1602-1611.